article · Annals of Innovation in Medicine
Malaria remains a significant public health concern in Sudan, particularly among children, with Plasmodium falciparum as the dominant species. Artemether-Lumefantrine (AL) is the recommended first-line treatment for uncomplicated malaria; however, rising treatment failure rates necessitate further evaluation. This study assessed the therapeutic efficacy of AL in children aged 6 months to 16 years at Wad-Medani Pediatric Teaching Hospital, Gezira State. A prospective single-arm interventional study was conducted, enrolling 80 patients and following 70 through a 28-day treatment regimen. Clinical assessments, parasitological responses, and adherence evaluations were performed. The results showed a cure rate of 91.5%, with significant adherence-related outcomes (p<0.05). Early treatment failure (ETF) was observed in 5% of cases, with no late clinical or parasitological failures reported. Clinical pharmacist interventions improved awareness and adherence among healthcare providers and caregivers. The study concluded that AL remains highly effective for treating uncomplicated malaria in Sudan, although targeted interventions to enhance adherence are critical for sustained efficacy.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.59652/aim.v3i2.456
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.